抄録
Angiogenesis is an essential process in the progression of malignant tumors. Whereas pan-endothelial markers, such as CD34, are generally used in evaluation of angiogenesis, pan-endothelial antibodies react not only with developing vessels but also with normal vessels simply trapped within tumor tissues. It has been recently reported that an anti-CD 105 antibody preferentially reacts with activated endothelial cells in angiogenic tissues such as tumor tissues. Thus the efficacy of anti-CD 105 monoclonal antibody (mAb) in evaluating angiogenesis in pancreatic tumors was assessed. We immunohistochemically investigated 27 cases of pancreatic tumor (including 16 cases of malignant tumor, 2 cases of borderline malignancy and 9 cases of benign tumor) . Intratumoral microvessel density (IMVD) was determined with an anti-CD34 mAb (CD34-IMVD) and with an anti-CD 105 mAb (CD 105-IMVD) . More vessels were generally recognized by the anti-CD34 mAb than by the anti-CD 105 mAb. The mean CD34-IMVD in malignant tumors and in borderline/benign tumors was 136.13±56.71 and 120.55±40.65, respectively, a result which exhibited no significant difference (P>0.05) . In contrast, the mean CD 105-IMVD in malignant tumors and in borderline/benign tumors was 19.44±16.53 and 6.36±8.03, a statistically significant difference with P<0.05. Hence anti-CD 105 mAb proved to be superior to anti-CD34 mAb in evaluating angiogenesis in pancreatic tumors.
